Haemonetics Corp. (HAE) Company Profile & Statistics

Haemonetics Corp.
HAE
(NYSE)
Open
89.05
-0.17 (-0.19%)
in:usd•As of: Nov 18, 2024 12:36 UTC -5
Open
89.34
High
89.75
Low
88.57

About Haemonetics Corp.

CEO

Christopher A. Simon

Headquarters

125 summer street

boston, ma 02110, united states

Auditor

Ernst & Young LLP

Employees

3,657

Share Holders

101

Website

www.haemonetics.com

Industry

medical specialties

Sector

health technology

Company Overview

Haemonetics Corp. provides blood management solutions to customers encompassing blood and plasma collectors, hospitals and health care providers globally. Its portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain, helping better clinical outcomes. It acquired Pall Corporation's blood collection, filtration and processing product lines. It entered into a long-term supply agreement with Pall. The company acquired Hemerus Medical. It operates under 3 segments: Plasma, Blood Center, and Hospital. Plasma includes plasma collection devices and disposables, plasma donor management software, anticoagulant and saline sold to plasma customers. Blood Center includes blood collection and processing devices and disposables for red cells, platelets and whole blood as well as related donor management software. Hospital includes three product lines, namely, Hemostasis Management, Cell Salvage and Transfusion Management.

Haemonetics Corp. Statistics

Valuation Measures

Market Capitalization ²	4.47B
Enterprise Value	5.40B
Enterprise Value/EBITDA (ttm)	18.46
Price to Earnings Ratio (ttm)	21.87
Price to Book (mrq)	5.20
Price to Sales (ttm)	3.29
Price to Cash (ytd)	14.74

Profitability

Gross Margin (ttm)	52.61%
Operating Margin (ttm)	15.35%
Profit Margin (ttm)	9.11%
Return on Equity (ttm)	22.67%
Return on Invested Capital (ttm)	6.31%
Return on Assets (ttm)	8.83%

Income Statement

Revenue (ttm)	1.36B
Revenue Per Share (ttm)	27.10
Gross Profit (ttm)	716.13M
EBITDA (ttm)³	292.40M
Net Income Avi to Common (ttm)	123.81M
Diluted EPS (ttm)	2.41

Share Statistics

Beta (5Y Monthly)	0.32
52-Week Change	7.38%
S&P500 52-Week Change	29.65%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	50.22M
Dividend Yield	0.00%
Float ⁴	49.32M
% Held by Insiders	1.80%
% Held by Institutions	99.67%

Balance Sheet

Total Cash (mrq)	299.28M
Total Cash Per Share (mrq)	5.96
Total Debt (mrq)	1.22B
Total Debt/Equity (mrq)	139.38%
Current Ratio (mrq)	3.49%
Quick Ratio (mrq)	2.09%
Book Value Per Share (mrq)	17.44

Cash Flow

Operating Cash Flow Per Share (ytd)	0.42
Free Cash Flow (ytd)	26.86M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Haemonetics Corp.

Trade With A Regulated Broker